Navigation Links
Arete Therapeutics Bolsters Management Team
Date:10/29/2008

Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery

HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.

"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."

Dr. MacIntyre comes to Arete after more than 22 years with Merck Research Laboratories, where he held positions of escalating importance, most recently as Vice President of Pharmacology. Under his leadership, Dr. MacIntyre's team identified and validated several compounds now commercially available or in clinical trials for a variety of diseases and conditions including emesis, diabetes, obesity, hypertension, hyperlipidemia, pain, urinary incontinence and immuno-inflammatory disorders. In addition to his experience in discovery and development, Dr. MacIntyre evaluated numerous in-licensing candidates and served as a member of several joint research committees for Merck's joint ventures and collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and experimental pathology from the University of Cambridge. H
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
8. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
9. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The report, "Synthetic ... Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene ... Biomaterials, Bioremediation) - Global Forecast to 2018", ... threats, opportunities, and challenges. , Browse 99 ... through 185 pages and in-depth TOC of ...
(Date:11/21/2014)... November 21, 2014 Why did Stephen ... Albert Einstein so instantly recognizable? Why have they become ... astronomer and author Hilton Ratcliffe seeks out the answers ... at all to do with science. In " Stephen ... , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and nine month periods ended September 30, 2014.  Biorem,s complete 2014 ... ( www.sedar.com ). Financial Summary:Three-months ended September ... except per share data) , 2014 , ... 2,282 , 5,281 , 6,715 ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Brings Together,Policy and Innovation Experts, WASHINGTON, ... health,care economists and physician-innovators today highlighted the ... care and helping to,reduce health care costs. ... Innovation, Patients, Society," was part of AdvaMed ...
... Stanford, Berkeley, UPenn Partner with ... SANTA CRUZ, Calif., Oct. 2 According to the ... and,post-doctorates are in the United States today. With only ... universities, there,is an emerging need to find more quality ...
... Hall of Fame Coach Jim Calhoun Credits Early ... Day two of AdvaMed 2007:,The MedTech Conference will ... in medical technology as well as speakers on the,diversity ... technology,sector. The conference runs Oct. 1 through Oct. 3., ...
Cached Biology Technology:Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference 2Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference 3Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... known as the winter vomiting bug, is one of the ... highly contagious, causing vomiting and diarrhea, and the number of ... have to let the virus run its course for a ... associated with outbreaks of hNoV but it remains difficult to ...
... home to countless microorganisms that we can,t see, but these ... known as the skin microbiome - contribute to our health ... from pathogens, and mediating skin disorders. In a new study, ... in a contact sport, using roller derby as their model ...
... French . Researchers at the University of Montreal,s ... new mechanism that allows some cells in our body to move ... soldiers depicted in the Asterix series. Collective cell migration is an ... is also used by cancerous cells to disseminate efficiently in the ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Biology Products: